English Polski
Vol 15, No 1 (2020)
Review paper
Published online: 2020-02-28

open access

Page views 556
Article views/downloads 532
Get Citation

Connect on Social Media

Connect on Social Media

A fresh perspective on anticoagulant therapy in patients with cancer in the era of NOAC

Agnieszka Bureta1, Bartosz Kwiatkowski1, Małgorzata Lelonek1
Folia Cardiologica 2020;15(1):27-33.

Abstract

Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent years, oncological patients have been given heparin and vitamin K antagonists. Nowadays, non-vitamin K antagonist oral anticoagulants (NOAC) are becoming increasingly widely used. Based on the current state of knowledge, NOAC drugs can be used in anticoagulant treatment of cancer patients with caution, i.e. after assessing the bleeding risk and a risk-benefit analysis of anticoagulant therapy, as well as of the drug interactions between oncological drugs and the NOAC group.

Article available in PDF format

View PDF Download PDF file